Rx Medicare

Scientists have developed an alternative method for producing the active ingredient in Tamiflu?, the mainstay for fighting H1N1 and other forms of influenza. The new process could expand availability of the drug by reducing its cost, which now retails for as about $8 per dose. Their study is in ACS’ Organic Letters, a bi-weekly journal…

Read More…

Related Posts

• NanoViricides, Inc. To Present Anti-Influenza Drug Candidate FluCide™ Studies At The Influenza Congress 2009
• Anti Flu Drug Did Well In Final Stage Trials Says Japan’s Daiichi Sankyo
• Pandemic Flu, Like Seasonal H1N1, Shows Signs Of Resisting Tamiflu
• Update On Person To Person Spread Of Swine Flu Resistant To Tamiflu, Wales
• WHO Investigates Cases Of H1N1 Drug Resistance In U.S., Britain
• FDA Warns Of Unapproved And Illegal H1N1 Drug Products Purchased Over The Internet
• Paradigm Shift Needed To Combat Drug Resistance
• Publix Pharmacies To Compound Tamiflu Into Oral Suspension
• Tamiflu Metabolite Measured In Japanese Sewage Discharge, River Water
• Walgreens To Compound Tamiflu Oral Suspension For Children In Response To Supply Shortage
• La canción de la Influenza (Versión Original HQ)
• China Aoxing Pharmaceutical Company Announces Submission Of NDA Of Its Leading Narcotic Drug For The Treatment Of Acute Moderate To Severe Cough
• Most Appropriate Treatment Strategy: Extension Of Vaccination Policy Or Prescription Of Anti-Influenza For Healthy Adults?
• Stanford Research Assesses Use Of Tamiflu, Relenza To Prevent Flu
• Funxional Successfully Completes Initial Clinical Trial Of FX125L, An Anti-Inflammatory Drug With A Novel Mechanism Of Action

Tags: anti, drug, efficacy, expensive, tamiflu, toward, version

This entry was posted on Saturday, January 16th, 2010 at 9:01 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.